Select year
BioGaia AB’s Nomination Committee for the Annual General Meeting 2027 has been appointed based on the ownership structure as of June 30, 2026. The Nomination Committee for the Annual General Meeting 2027 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Alexander Kahane (Chairman of the […]
BioGaia's (NASDAQ: BIOG) financial report for the third quarter of 2026 will be published at approximately 8:00 AM CEST on October 22, 2026. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website. CEO Theresa […]
BioGaia AB (NASDAQ Stockholm: BIOG) will host a Capital Markets Day in London on December 8, 2026. The Capital Markets Day will be held as an in-person event in London, and the presentations will also be broadcast live. During the event, members of BioGaia's leadership team, including Theresa Agnew, President and Chief Executive Officer; Alexander […]
BioGaia announces the launch of BioGaia® Colus®, a probiotic formulation designed to promote colon health through a strain-specific and targeted delivery approach. The product expands BioGaia’s science-based probiotic portfolio for adult gut health with a supplement developed for the lower gastrointestinal tract. The product contains the proprietary probiotic strain L. reuteri BG-R59®. This new product […]
BioGaia AB has signed a new long-term exclusive distribution agreement with Recordati for Spain and Portugal, building on the companies’ existing collaboration in the Iberian market and partnership in Italy. The agreement covers the distribution of BioGaia’s products in Spain through Casen Recordati and in Portugal through Jaba Recordati. Spain and Portugal represent important markets […]
SECOND QUARTER 2026 Net sales amounted to SEK 440.9 million (404.7), an increase of SEK 36.2 million, an increase excluding currency effects of 12% (9% including currency effects). Net sales in the Pediatrics segment amounted to SEK 331.7 million (310.1), an increase excluding currency effects of 9% (7% including currency effects). Net sales in the […]
BioGaia’s (NASDAQ: BIOG) financial report for the second quarter of 2026 will be published at approximately 8:00 AM CEST on July 17, 2026. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website. CEO Theresa […]
BioGaia AB’s subsidiary, Biogaia New Sciences AB, is expanding its BioGaia® Skincare portfolio with two new products and an updated design across the full range. The expanded skincare line reinforces BioGaia’s ambition to apply its microbiome expertise beyond gut health, oral health and immune health, supporting healthy and balanced skin from the earliest stages of […]
The Annual General Meeting of BioGaia AB (publ) was held on 7 May 2026 at 4.00 pm at Klara Konferens & Happynings, Klarabergsviadukten 90, Stockholm, at which the shareholders passed the resolutions set out below. Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet. Discharge from liability […]
Be the first to know all about the latest news from BioGaia.
Subscribe
